NEXUS BIOPHARMA INC — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/46e18497-748b-406c-9867-573168aa66ae/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2016 | $-686.1k | 2016-03-01 – 2017-02-28 | evidence 0001213900-17-007185 |
| FY 2015 | $-1.2M | 2015-03-01 – 2016-02-29 | evidence 0001213900-17-007185 |
| FY 2014 | $-1.4k | 2014-01-01 – 2014-12-31 | evidence 0001477932-15-002597 |
| FY 2013 | $-15.3k | 2013-01-01 – 2013-12-31 | evidence 0001477932-15-002228 |
| FY 2012 | $-140.7k | 2007-07-17 – 2013-03-31 | evidence 0001524777-13-000239 |
| FY 2011 | $-127.8k | 2007-07-17 – 2012-03-31 | evidence 0001524777-12-000141 |
| FY 2010 | $-20.4k | 2010-01-01 – 2010-12-31 | evidence 0001524777-12-000114 |
| FY 2009 | $-28.4k | 2009-01-01 – 2009-12-31 | evidence 0001524777-12-000114 |
| FY 2008 | $-43.9k | 2008-01-01 – 2008-12-31 | evidence 0001524777-12-000114 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).